Veliparib is being developed as an improvement on previous drugs, for the treatment of advanced or metastatic non-squamous non-small cell lung cancer. In combination with carboplatin and paclitaxel it will, if licenced, offer an additional treatment option for patients with this indication.
Veliparib (ABT-888) with carboplatin and paclitaxel for advanced or metastatic non-squamous (current or former smokers) non-small cell lung cancer
![featured image](https://www.io.nihr.ac.uk/wp-content/uploads/2022/01/Patients-Public_Motifs_Conduction-broadcasting_RGB-scaled_edit1233.jpg)
Interventions:
Carboplatin (Paraplatin)
, Paclitaxel (Taxol; paclitaxel albumin)
, Veliparib (ABT-888; NSC 737664)
Indications:
Non-small-cell lung cancer (NSCLC)
Therapeutic Areas:
Lung and Respiratory Cancer
Year:
2017